Strategic partnerships HRI’s extensive network with over 110 collaborations across 44 countries and partnerships with entities like the Charles Perkins Centre, Royal Prince Alfred Hospital, Sydney Local Health District, and Sydney Health Partners presents multiple co-development, grant collaboration, and translational research opportunities for industry partners and biotech firms seeking access to cardiovascular expertise and clinical trial pathways.

Funding momentum With a revenue range of 25 to 50 million and recent NHMRC funding success delivering over 4 million in grants, there is a favorable funding environment to propose research collaborations, sponsored studies, technology licensing, and product development programs aligned with cardiovascular research priorities.

Center expansions The launch of the Centre for Peripheral Artery Disease and new senior appointments such as Deputy Director and Director of Research signal growing institutional capacity and focus areas, offering opportunity for targeted research contracts, contract research services, and instrument or device testing collaborations.

Clinical translation HRI aims to translate discoveries into clinical trials and develop new drug therapies and devices, making them an ideal partner for pharmaceutical and medical device companies seeking preclinical to clinical transition expertise, trial design support, and access to cardiovascular patient cohorts.

Talent and branding Recognized as a Best Workplace and a Highly Cited Researcher, HRI demonstrates strong talent magnetism and scientific credibility, enabling premium sponsorships, executive partnerships, ambassador programs, and mechanisms to co-brand large-scale cardiovascular initiatives.